Huang, Xiangang http://orcid.org/0000-0001-8948-7879
Kon, Edo
Han, Xuexiang
Zhang, Xingcai http://orcid.org/0000-0001-7114-1095
Kong, Na
Mitchell, Michael J. http://orcid.org/0000-0002-3628-2244
Peer, Dan http://orcid.org/0000-0001-8238-0673
Tao, Wei http://orcid.org/0000-0002-4277-3728
Article History
Received: 16 August 2021
Accepted: 8 June 2022
First Online: 18 August 2022
Competing interests
: D.P. declares the following competing financial interest(s): D.P. receives licensing fees (to patents on which he was an inventor) from, invested in, consults (or on scientific advisory boards or boards of directors) for, lectured (and received a fee) or conducts sponsored research at TAU for the following entities: ART Biosciences, BioNtech SE, EPM Inc., Earli Inc., Kernal Biologics, Merck, Newphase Ltd., NeoVac Ltd., RiboX Therapeutics, Roche, SirTLabs Corporation, Teva Pharmaceuticals Inc. The other authors declare no competing interests.
Free to read: This content has been made available to all.